Graphite Bio (Graphite Bio) Cash Flow from Financing : $0.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Graphite Bio Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Graphite Bio paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Graphite Bio spent $0.00 Mil on financial activities for the three months ended in Dec. 2023.

Graphite Bio Cash Flow from Financing Historical Data

The historical data trend for Graphite Bio's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Graphite Bio Cash Flow from Financing Chart

Graphite Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

30.08

417.47

0.60

0.19

Graphite Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial												0.24	-0.01	0.12	0.01	0.07

Graphite Bio Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Graphite Bio's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	-0.067	+	0	+	0	+	0	+	0.257
=	0.19

Graphite Bio's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.19 Mil.

Graphite Bio (NAS:GRPH) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Graphite Bio's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Graphite Bio's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Graphite Bio's net issuance of debt for the three months ended in Dec. 2023 was $0.00 Mil. Graphite Bio received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Graphite Bio's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Graphite Bio paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Graphite Bio's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Graphite Bio received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Graphite Bio's other financing for the three months ended in Dec. 2023 was $0.00 Mil. Graphite Bio received $0.00 Mil on other financial activities.

Graphite Bio Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Graphite Bio's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Graphite Bio (Graphite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Graphite Bio Inc (NAS:GRPH) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskins Way, Suite 210, South San Francisco, CA, USA, 94080

Website

https://www.graphitebio.com

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.

Executives

Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Phil Gutry	officer: CHIEF BUSINESS OFFICER	400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Alethia Young	officer: Chief Financial Officer	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Versant Ventures Vi Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Matthew Porteus	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Katherine V Stultz	officer: CHIEF OPERATING OFFICER	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Abraham Bassan	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
L.p. 436,	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rizzuto Carlo	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Smital Shah	director	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080